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Summary
Primary T helper 2 cells are heterogeneous, express-
ing subsets of cytokines at varying levels. Mecha-
nisms controlling this spectrum of phenotypes are
still unclear. The ETS family transcription factor PU.1
is expressed in Th2 but not Th1 cells. Th2 cytokine
production is decreased in cultures transduced with a
PU.1-expressing retrovirus and increased in Th2 cells
following RNAi that decreases PU.1 expression. In
primary cultures, PU.1 expression is restricted to a
subpopulation of Th2 cells that express CCL22 and a
subset of Th2 cytokines. PU.1 regulates the Th2 phe-
notype by interfering with GATA-3 DNA binding with-
out altering GATA-3 protein levels. Thus, the expres-
sion of PU.1 in subsets of Th2 cells establishes a
defined cytokine profile and contributes towards es-
tablishing the spectrum of cytokine production ob-
served in Th2 populations.
Introduction
T helper 2 (Th2) cells, defined as effector cells that
secrete cytokines including IL-4, IL-5, IL-10, and IL-13
are critical for the development of atopic immune re-
sponses (Abbas et al., 1996). Th2 differentiation is pro-
moted by IL-4 and the activation of Stat6. The mecha-
nism of Stat6 promoting the Th2 phenotype likely
includes induced expression of Th2-specific transcrip-
tion factors such as GATA-3 and c-maf (Glimcher and
Murphy, 2000). Th2 populations are heterogeneous in
nature. Examination of Th2 populations in vivo and
in vitro demonstrates that while these populations
secrete multiple Th2 cytokines, individual cells only ex-
press subsets of cytokines (Bucy et al., 1995; Sommer
et al., 1998; Jankovic et al., 2000; Karulin et al., 2000).
In addition, not all cells in a population secrete similar
levels of cytokine. Recent studies of cells separated
based on low or high IL-4 secretion have demonstrated
that a low or high cytokine secretion pattern is a herita-
ble and stable phenomenon (Guo et al., 2002). While
several negative regulators of Th2 cytokine expression
have been described, it is not clear how they integrate
into the heterogeneous population phenotype (Gourley*Correspondence: mkaplan2@iupui.edu
3 These authors contributed equally to this work.et al., 1999; Miaw et al., 2000; Lieberson et al., 2001;
Zhou et al., 2001; Komine et al., 2003; Kusam et al.,
2003). Thus, the mechanism that drives the Th2 mosaic
of cells expressing varying levels of cytokine as well as
distinct subsets of individual cytokines is unclear.
PU.1, an ETS family transcription factor, also iden-
tified as the spleen focus forming virus proviral integ-
ration site-1 (Spi-1) (Moreau-Gachelin et al., 1988; Klemsz
et al., 1990) activates many genes associated with lin-
eage-specific development (Nelsen et al., 1993; Fisher
and Scott, 1998; DeKoter et al., 2002). Two PU.1 locus-
targeted mouse models have been generated and,
while there are distinctions in the models, examination
of fetal liver and other hematopoietic organs demon-
strate the absence or attenuation of macrophage, neu-
trophil, mast cell, and B cell development and function
(Scott et al., 1994; McKercher et al., 1996). PU.1 RNA
is observed in splenic T cells but a role for PU.1 protein
in T cells has not been established (Klemsz et al., 1990;
Anderson et al., 1999). PU.1-deficient mouse models
demonstrated decreased T cell development in vivo and
in thymic organ culture (Spain et al., 1999). However,
chimeras of PU.1-targeted ES cells and wild-type or
Rag2−/− blastocysts, or PU.1−/− fetal liver radiation chi-
meras with wild-type or Rag2−/− mice did not develop
PU.1-deficient T cells (Scott et al., 1997; Colucci et al.,
2001; Dahl et al., 2002). PU.1 is expressed in lymphoid
progenitors and is still present in CD4−CD8− thymocytes
at the earliest stage of development (CD25+CD44−),
though elimination of PU.1 is required for normal T cell
development (Anderson et al., 2002). As PU.1 expres-
sion in developing T cells is extinguished, expression
of GATA-3 is induced, a step critical for the develop-
ment of T cells (Ting et al., 1996; Anderson et al., 2002).
Furthermore, PU.1 and GATA factors can physically and
functionally interact (Rekhtman et al., 1999; Zhang et
al., 2000a; Walsh et al., 2002). However, the lack of a
model wherein PU.1-deficient T cells develop in vivo
has prevented an examination of PU.1 biology in ma-
ture T cells.
Since GATA-3 expression is modulated during T helper
cell differentiation, we examined the expression of PU.1
in T helper subsets. We found PU.1 expressed in Th2
cells but not in Th1 cells. Retroviral expression of PU.1
in developing or established Th2 cells reduced, while
use of PU.1 RNAi increased, Th2 cytokine secretion. In
primary Th2 cultures, separated based on the level of
IL-4 production, PU.1 expression was primarily ob-
served in IL-4-low cells, where it was coexpressed with
a subset of Th2 cytokines. Thus, PU.1 is expressed in
Th2 cells and regulates cytokine production contribut-
ing towards a spectrum of Th2 cytokine profiles.
Results
PU.1 in Th2 Cells
Since PU.1 and GATA factors have been shown to func-
tionally interact (see Introduction), we initially examined
differentiated Th1 and Th2 cells which have respec-
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694tively, low and high levels of GATA-3, for expression of w
PU.1. Purified CD4+ cells were differentiated to Th1 or s
Th2 cells and left unstimulated or stimulated with anti- a
CD3. Northern analysis demonstrated that PU.1 is c
expressed in Th2 cells but not Th1 cells (Figure 1A). t
During Th1 differentiation of naïve CD4+ T cells, PU.1 p
expression is extinguished and the mRNA is no longer a
detectable by real-time PCR by 5 days after culture i
(Figure 1B). In contrast, PU.1 mRNA is induced under s
Th2 conditions and while expression decreases over t
the culture period, corresponding with increasing s
GATA-3 expression, levels of PU.1 are still readily de- w
tectable after 5 days of culture (Figure 1B). Expression e
in Th2 cells requires Stat6 as Th2 cultures of Stat6-defi- d
cient cells lack detectable expression of PU.1 (Figure o
1A). Furthermore, Stat4 is not required for elimination i
of PU.1 expression during Th1 development (Figure (
1A). PU.1 protein was detected in nuclear extracts of
Th2, but not Th1 cells and could be precipitated from t
Th2 extracts using a biotinylated oligonucleotides con- m
taining a PU.1 binding site (Figures 1C and 1D). To- m
gether, these results demonstrate that there is re- s
stricted expression of PU.1 in T helper subsets. a
A
dFunction of PU.1 in Th2 Cells
tWe then wanted to examine the function of PU.1 in Th2
lcells. In mast cells, PU.1 has been shown to bind to an
(intronic enhancer in the IL-4 gene (Henkel and Brown,
i1994) and positively regulate IL-4 gene expression. We
Tinitially postulated that PU.1 might perform a similar
frole in Th2 cells. To test this, we generated a PU.1-
lexpressing bicistronic retroviral vector (Figure 2A). Th2
cells were transduced on the second day of a one- fFigure 1. PU.1 Expression in Th2 Cells
(A) RNA was isolated from Th1 or Th2 cul-
tures generated from mice of the indicated
genotypes following stimulation with or with-
out anti-CD3 for the indicated number of
hours and was probed for PU.1 expression.
Northern blots were probed with TCRα as a
loading control. The data are representative
of five experiments.
(B) RNA was isolated daily from freshly iso-
lated naive CD4+ cells (day 0) and from dif-
ferentiating Th1 and Th2 cultures over 5
days. PU.1 (top) and GATA-3 (bottom) ex-
pression was determined by real-time PCR
with samples being normalized to the ex-
pression of β2-microglobulin mRNA. Error
bars indicate mean ± SEM. The data are re-
presentative of two experiments.
(C) Cytoplasmic or nuclear extracts (100 or
200 g) from Th1 or Th2 cultures were immu-
noblotted with anti-PU.1. Blots were reprobed
with PARP as a nuclear loading control. The
data are representative of three experiments.
(D) Cytoplasmic or nuclear extracts (500 g)
from Th1 or Th2 cells were incubated with a
biotinylated PU.1 binding oligonucleotide
and complexes were precipitated with strep-
tavidin-agarose. Precipitates were immu-
noblotted with anti-PU.1. Extract (200 g)
used for the DNA binding assay was immu-
noblotted in parallel (bottom panel). The data
are representative of two experiments.eek culture and were then sorted for EGFP expres-
ion. The sorted cells were stimulated with anti-CD3
nd assessed for cytokine production by intracellular
ytokine staining and ELISA. Analysis demonstrated
hat retroviral expression of PU.1 in Th2 cells decreased
roduction of Th2 cytokines, including IL-4, IL-5, IL-10,
nd IL-13 (Figures 2B and 2C). Transduction of PU.1
nto Th1 cultures had minimal effects on IL-4 expres-
ion (data not shown). We then wanted to determine if
he negative effect could only occur during the initial
tages of Th2 differentiation (first week of culture) or
hether PU.1 expression could also decrease cytokine
xpression in established cells. Th2 cells were trans-
uced with PU.1-expressing retrovirus during the sec-
nd week of culture. PU.1 expression was also effective
n decreasing cytokine expression in long-term cultures
Figure 2D).
To define the structural requirements for PU.1 func-
ion in Th2 cells, we transduced CD4+ T cells with PU.1
utant retroviruses that lacked a transactivation do-
ain, a PEST domain, or had a point mutation that de-
troyed DNA binding activity (Klemsz and Maki, 1996)
nd analyzed as described above (Figures 2E and 2F).
ll mutant proteins were equal to intact PU.1 in
ecreasing IL-4 production (Figure 2G). The PEST mu-
ant (118–160) was as effective as intact PU.1 in regu-
ating cytokine production. The DNA binding mutant
R232G) was somewhat less effective than intact PU.1
n reducing IL-5, IL-10, and IL-13 production (Figure 2G).
he activation domain mutant (33–100) was equally ef-
ective in regulating IL-4 and IL-5, while it was slightly
ess effective at regulating IL-10 and slightly more ef-
ective at regulating IL-13. However, these latter effects
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(A) Schematic of retroviral vectors used for infection of primary T cells
(B) EGFP+ cells from differentiating Th2 populations transduced with control or PU.1-expressing retrovirus on the second day of differentiation
and cultured for an additional three days after infection were restimulated with anti-CD3 and treated with Monensin for the last 2 hr of a 5 hr
incubation before intracellular staining of cytokine expression. Analysis was performed on 5000 EGFP+ events. The data are representative
of two experiments.
(C) Th2 cultures infected as in (B) were sorted after 5 days in culture to isolate EGFP (+) and (−) populations and restimulated with anti-CD3.
Supernatants were collected after 24 hr and analyzed for cytokine levels by ELISA. The asterisk indicates a significant difference from Vector
EGFP (+) cells, p < 0.05. Results are means of duplicate samples and representative of more than 10 experiments.
(D) CD4+ T cells were cultured under Th2 conditions for 6 days and rested overnight in IL-2. Cells were then cultured with Th2 cytokines and
infected with control or PU.1-expressing retroviruses. EGFP (+) and (−) cells were sorted by flow cytometry, and after a total of 11 days in
culture, cells were restimulated with anti-CD3. Supernatants were collected after 24 hours and analyzed for cytokine levels by ELISA. The
asterisk indicates a significant difference from Vector EGFP (+) cells, p < 0.05. Results are an average of two experiments.
(E) Schematic of PU.1 domain structure and mutants used for analysis of function.
(F) Expression of retroviral PU.1 and PU.1 mutants in primary T cells. Extracts (50 g) from differentiated EGFP+ Th2 cells were immunoblotted
for PU.1 expression and GAPDH as a control. Sizes of PU.1 and PU.1 mutants are shown at the right side of the panel. In lanes with multiple
translation products, a dot indicates full-length bands.
(G) EGFP+ cells were prepared as in (B) and analyzed as in (C) following infection with PU.1 or PU.1 mutant-expressing retroviruses. The
asterisk indicates a significant difference from Vector EGFP + cells, p < 0.05. The “#” symbol indicates a significant difference from PU.1
EGFP+ cells, p < 0.05. Results represent the average of three experiments.
All ELISA results are expressed as mean ± SEM.
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were modest, suggesting only a limited role for this s
domain. p
Previous studies of GATA-3 demonstrated that as it
induces Th2 differentiation, it also inhibits Th1 differen- m
tiation (Ouyang et al., 1998). To test if PU.1 increased p
markers of Th1 differentiation as it decreased Th2 cy- l
tokine production, we analyzed the expression of IFN-γ, m
fIL-12Rβ2, and IL-18Rα on wild-type Th2 cells following
ptransduction with control or PU.1-expressing retro-
Iviruses. Transduction with the PU.1-expressing ret-
drovirus did not increase expression of either receptor
band levels remained identical to those seen in non-
stransduced Th2 cells (Figure 3A). Similarly, ELISA analy-
isis of anti-CD3 induced cytokine levels showed that the
iamount of IFN-γ produced by PU.1-expressing cells
C
was similar to that produced by nontransduced Th2
u
cells (Figure 3B). Thus, PU.1 decreases Th2 cytokine s
secretion without resulting in increased Th1 development. l
u
f
PU.1 Expression Is Restricted to Low Cytokine p
Secreting Th2 Populations
As described in the Introduction, Th2 populations are D
heterogeneous in nature, expressing subsets of cyto- I
kines at varying levels. Using intracellular cytokine T4
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CFigure 3. Retroviral PU.1 Expression Does Not Result in a Th1 Phe-
notype u
t(A) FACS analysis of IL-12Rβ2 and IL-18Rα. Top, staining of Th1
and Th2 cells. Bottom, staining of Th2 cells transduced with control p
RV or PU.1-expressing RV. c
(B) Th1 cells, or Th2 cells transduced with control or PU.1-express- t
ing RV, were sorted, cultured and stimulated as in Fig. 2C. Levels t
of IFN-γ were determined by ELISA. Error bars indicate mean ±
cSEM. The data are representative of three experiments.
g
4staining, we can divide Th2 cells into IL-4-low and IL--high subsets (Figure 4A). Analysis of these subsets
or expression of other Th2 cytokines revealed percent-
ges of IL-5 and IL-10 single- and double-positive cells
n each of these populations (Figure 4A). Given this
eterogeneity, we speculated that PU.1 expression
ight segregate in cytokine-low populations. To test
his, Th2 cells were partitioned into IL-4-high and IL-4-
ow secretors using magnetic cytokine selection. ELISA
nalysis of supernatants from these selected cells con-
irmed differential cytokine secretion of Th2 cytokines,
ith similar low levels of IFN-γ expressed in these pop-
lations (Figure 4B). RNA from IL-4-high or IL-4-low Th2
ells was analyzed by Northern blot. Strikingly, PU.1 ex-
ression segregated in the IL-4-low population and was
ot detected in the IL-4-high population as assessed
y both Northern and Western blot (Figures 4C and 4D).
U.1 expression was also not observed in protein ex-
racts from Stat6−/− IL-4-low cells, confirming data in
igure 1A that PU.1 is not expressed in Th2 cultures in
he absence of Stat6 (Figure 4D). IL-4 mRNA expression
as expectedly seen only in the IL-4 selected popula-
ion (Figure 4C). This was also true of IL-5 expression,
hich partitioned to the IL-4-high population and not in
U.1-expressing cells. The partitioning effect was not
s dramatic with IL-10 or IL-13, which showed in-
reased expression in the IL-4-high population, but
onsiderable expression in the PU.1-expressing pop-
lation. By contrast, other Th2 genes such as IL-21 and
CR4 were expressed equally between these two pop-
lations. CCL22/MDC, which we have previously shown
o be expressed in Th2 cells (Zhang et al., 2000b), was
referentially expressed in PU.1-expressing IL-4-low
ells. The cosegregation of PU.1 and CCL22 suggested
hat PU.1 might be regulating this chemokine. To test
his we analyzed supernatants from PU.1 transduced
ells generated as in Figure 2C. CCL22 levels were
reatly increased following PU.1 transduction (Figure
E). These results demonstrate that PU.1 expression
orrelates with, and may direct the phenotype of, a
ubset of Th2 cells displaying a distinct cytokine ex-
ression profile.
We further examined heterogeneity using an in vivo
odel we have previously developed wherein mice ex-
ress a constitutively active Stat6 and have increased
evels of Th2 cytokine production, compared to control
ice (Bruns et al., 2003). We isolated splenic CD4+ cells
rom four mice and analyzed their cytokine secretion
atterns by intracellular cytokine staining (Figure 4F).
L-5- and IL-10- single and double positive cells were
etected in both IL-4-high and IL-4-low populations, al-
eit to a lower level than observed in vitro cultures
ince a lower percentage of cells are Th2 cells. To test
f PU.1 expression also correlates with this phenotype
n vivo, RNA was isolated from stimulated CD2:Stat6VT
D4+ T cells separated into IL-4-high and IL-4-low pop-
lations. Real-time PCR of these RNA samples demon-
trated that PU.1 mRNA was expressed at 5-fold higher
evels in the IL-4-low population than the IL-4-high pop-
lation (Figure 4G). Thus, PU.1 expression also identi-
ies Th2 cells in vivo with distinct cytokine expression
atterns.
ecreased PU.1 Expression in Primary Cultures
ncreases Th2 Cytokine Production
he ability of PU.1 to decrease Th2 cytokine levels ledus to predict that decreased PU.1 expression would re-
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(A) Wild-type Th2 cells were restimulated with anti-CD3 after 6 days in culture and analyzed as in Figure 2B. Populations were divided into
IL-4-high and -low (right side of panel, top and bottom, respectively) and analyzed for IL-5 and IL-10 staining.
(B) Wild-type Th2 cells were stimulated with anti-CD3 and purified based on their IL-4 secretion levels. Cells were rested overnight and
restimulated with anti-CD3 for 24, 48 or 72 hours. Cytokine levels were analyzed by ELISA. The data are representative of three experiments.
(C) RNA was purified from cells isolated as in (B) and subjected to sequential Northern analysis using cDNA probes for PU.1, Th2 cytokines/
receptors and TCRα, as a control. The data are representative of two experiments.
(D) Total protein extracts (400 g) from wild-type and Stat6−/− Th2 cultures separated as in (B) were immunoblotted with anti-PU.1 or anti-
GAPDH, as a control.
(E) Supernatants from Vector or PU.1 transduced cells (EGFP [+] or [−]) generated as in Figure 2C were analyzed for CCL22 levels by ELISA.
The data are representative of three experiments.
(F) Purified CD4+ T cells from CD2:Stat6VT mice were stimulated with anti-CD3 and analyzed as in Figure 2B. Results are representative of
four experiments.
(G) Purified CD4+ T cells from CD2:Stat6VT mice were stimulated with anti-CD3 overnight and separated into IL-4-high and IL-4-low popula-
tions. PU.1 expression was determined by real-time PCR following normalization of signal to β2-microglobulin expression. Error bars indicate
mean ± SD. The data are representative of two experiments.
All ELISA results are expressed as mean ± SEM.ciprocally increase cytokine production. The prenatal or
neonatal lethality of PU.1-deficiency and the inability
to generate PU.1-deficient T cells in chimeric animals,
impairs an examination of mature PU.1-deficient T cells.
An examination of PU.1 haploinsufficient Th2 culturesyielded a modest trend towards increased cytokine
production (data not shown). To further reduce PU.1 ex-
pression in cells, we employed RNAi and used a short
hairpin RNA (shRNA) expressed from a bicistronic ret-
rovirus transcribing from a RNA pol III promoter. Trans-
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nduction of the M12 B cell line with two separate PU.1
shRNAs reduced PU.1 expression w35% compared to G
icontrol cells (Figure 5A). We then transduced PU.1 +/−
Th2 cultures to determine effects on Th2 cytokine ex- D
wpression. Following the differentiation culture period,
cells were gated on GFP+ events and analyzed as in d
aprevious experiments. Expression of the PU.1 shRNA1
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mProduction
m(A) Nuclear extracts (50 g) from M12 cells transduced with control
wor two different PU.1-specific RNAi retroviruses and isolated by cell
sorting were immunoblotted with anti-PU.1 or anti-PARP as a con- t
trol. The ratio of PU.1/PARP and percent decrease in PU.1 expres- f
sion compared to control RNAi are indicated below. t
(B) Differentiating Th2 cultures from PU.1+/− mice were transduced (
with retrovirus expressing a control or PU.1-specific shRNA two
wdays after initial activation. Four days after transduction, cells were
astimulated with anti-CD3 and analyzed as in Figure 2B. The data
are representative of three experiments. t
(C) Average fold induction of cytokine production of PU.1 RNAi c
treated cells versus control cells analyzed in (B). Fold inductions of a
total IL-4-, IL-5-, or IL-10-cytokine-positive cells or double cyto- i
kine-positive (IL-4/IL-5-positive, or IL-4/IL-10 positive) cells, are
mshown. The data are representative of three experiments. The as-
fterisk indicates a significant difference from control RNAi values,
p < 0.05. Error bars indicate mean ± SEM.
esignificantly increased production of IL-4, IL-5, and IL-0 (p < 0.05), compared to transduced control Th2 cells
Figures 5B and 5C) and similar results were seen with
oth PU.1 RNAi vectors. Furthermore, increases were
ost dramatic in IL-4/IL-5- and IL-4/IL-10-double-posi-
ive populations, suggesting that diminishing PU.1 in-
reased the homogeneity of Th2 cytokine production.
unctional Interactions of PU.1 and GATA-3
U.1 interacts with GATA-3 in an in vitro binding assay
Rekhtman et al., 1999), and because GATA-3 is a mas-
er regulator of Th2 cytokine expression, it offered a
otential mechanism for cytokine regulation. To explore
he functional interaction of PU.1 and GATA-3, we took
dvantage of the fact that the deficiency of Th2 devel-
pment in Stat6-deficient T cell cultures can be res-
ued by introduction of a retrovirus expressing GATA-3
Ouyang et al., 2000). We employed a retrovirus ex-
ressing GATA-3 from a bicistronic transcript that also
ncodes the human CD4 (hCD4) gene (Figure 6A). Fol-
owing transduction of Stat6-deficient Th2 cultures with
U.1 and GATA-3 retroviruses we sorted populations
hat were hCD4 and EGFP-double positive (hCD4 RV +
ector RV, GATA-3 + Vector RV, or GATA-3 + PU.1 RV)
or cytokine analysis. Stat6-deficient cultures trans-
uced with the GATA-3-expressing and control ret-
ovirus secreted increased levels of IL-4, IL-5, and IL-
3 and decreased IFN-γ, compared to control vector
ransduced Stat6 cells (Figure 6B). Stat6-deficient T
ells expressing both PU.1 and GATA-3 had low levels
f Th2 cytokine expression, comparable to cultures
ransduced with control vectors. This supports a hy-
othesis wherein PU.1 interferes with GATA-3 function
n Th2 cells.
To further demonstrate that PU.1 and GATA-3 exist
n a complex, GATA-3 was immunoprecipitated from
hoenix cells transfected with GATA-3 and full-length
U.1 or mutant PU.1 cDNAs. GATA-3 was able to copre-
ipitate PU.1 and both the activation and PEST domain
utants of PU.1 (Figure 6C). There was significantly di-
inished precipitation of the PU.1 DNA binding mutant,
hich correlates with the decreased ability of this mu-
ant to alter cytokine production (Figure 2G). Trans-
ected Phoenix cells overexpress PU.1 at levels five
imes higher than in RAW cells, a macrophage cell line
Figure 6D). IL-4-low Th2 cells and EL4 cells transduced
ith PU.1-expressing retroviruses (EL4-PU.1) express
bout 10-fold less PU.1 than RAW cells and about one-
hird of the levels of PU.1 in transduced primary Th2
ells (Figure 6D). To confirm interactions between PU.1
nd GATA-3 at more physiological expression levels we
mmunoprecipitated PU.1 from EL4-PU.1 cells and pri-
ary Th2 cells and observed coprecipitation of GATA-3
rom extracts of both populations (Figures 6E and 6F).
To further address the mechanism of GATA-3 interfer-
nce by PU.1, we first tested the levels of GATA-3 able
o bind DNA in EL4-PU.1 and control cells using a bioti-
ylated oligonucleotide pull-down assay (Figure 7A).
ATA-3 DNA binding activity was less in PU.1-express-
ng cells than in control cells. Despite the reduction in
NA binding activity, total GATA-3 protein expression
as similar between the two cell lines (Figure 7B). To
emonstrate that GATA-3 DNA binding activity was also
ffected in primary Th2 populations, we performed sim-ilar experiments in Th2 cells separated based on IL-4
Heterogeneity in Th2 Cells
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(A) Schematics of retroviral vectors used in
primary T cell transductions.
(B) Stat6−/− Th2 cultures were transduced
with control (vector or hCD4 RV), GATA-
3-expressing, and PU.1-expressing retro-
viruses. Populations that were hCD4 and
EGFP-double positive (hCD4 RV + Vector RV,
GATA-3 + Vector RV, or GATA-3 + PU.1 RV)
were isolated by flow cytometry. Purified
cells were stimulated with anti-CD3 and cy-
tokine levels were tested by ELISA. Data re-
present mean ± SEM. The asterisk indicates
a significant difference from Vector RV +
hCD4 RV transduced cells, p < 0.05.
(C) GATA-3 and PU.1, PU.1 mutant or empty
retroviral vectors were transfected into Phoe-
nix cells. GATA-3 was immunoprecipitated
from total cell extracts and precipitates were
immunoblotted for PU.1. The expression of
GATA-3 and PU.1 or PU.1 mutants was de-
tected in total cell extracts by immunoblot.
(D) Densitometry analysis of immunoblots of
PU.1 expression in IL-4-low Th2 cells com-
pared to other cells with transduced PU.1,
and RAW cells.
(E) PU.1 was immunoprecipitated from PU.1
transduced EL4 cell extracts. Precipitates
were immunoblotted for GATA-3 and PU.1.
(F) PU.1 was immunoprecipitated from pri-
mary Th2 cells. Precipitates were immu-
noblotted for GATA-3 and PU.1. The amount
of GATA-3 and PU.1 present in extracts be-
fore immunoprecipitation (input) is shown
below.secretion. DNA binding activity was also greatly dimin-
ished in primary IL-4-low Th2 cells compared to IL-4-
high cells, while total GATA-3 protein was similar be-
tween these populations (Figure 7C). To test whether
PU.1 prevented GATA-3 from binding to cytokine loci
in vivo, we performed GATA-3-chromatin immunopreci-
pitation assays from IL-4-high and IL-4-low Th2 cells
and assayed for the presence of IL-4 3# enhancer DNA
(DNase hypersensitivity site VA), a site known to bind
GATA-3 (Avni et al., 2002). IL-4 VA DNA was present in
the GATA-3 precipitates from IL-4-high cells but at
greatly decreased levels in IL-4-low cells (Figure 7D),
consistent with the in vitro binding data. As a control,
IL-4 promoter DNA was not found in GATA-3 immuno-
precipitates in either IL-4-high or IL-4-low cells. Thus,
in IL-4-low Th2 cells, PU.1 interacts with, and de-
creases the DNA binding activity of, GATA-3.
Discussion
PU.1 is well studied as a regulator of myeloid and B cell
development and function. In this report, we demon-
strate a novel role for PU.1 in Th2 function. PU.1 ex-pression regulates Th2 cytokines in primary popula-
tions and defines a subpopulation that expresses low
amounts of some Th2 cytokines, normal amounts of
others and exclusive expression of the Th2 chemokine
CCL22. PU.1 functions, at least partially, by interfering
with GATA-3 DNA binding. Thus, the expression of PU.1
in Th2 subsets establishes a cytokine profile that distin-
guishes these cells from IL-4-high cells (Figure 7E).
PU.1 may define only one of many phenotypes in the
spectrum of Th2 cells, but importantly, contributes to
the mosaic of Th2 populations.
Models of T helper cell differentiation have evolved
over the last decade to incorporate our increasing
knowledge of the process. Initially, many of the tran-
scription factors that regulate IL-4 stimulated Th2 de-
velopment and cytokine expression, Stat6, c-maf and
GATA-3, were identified (Glimcher and Murphy, 2000).
Further study demonstrated that IL-4 stimulates an in-
structive program resulting in the activation of Stat6
and the increased expression of GATA-3 (Kurata et al.,
1999; Farrar et al., 2001). Cell division enhances T
helper cell specific cytokine production, possibly re-
flecting a requirement for chromatin remodeling of Th2
Immunity
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Binding
(A) Biotinylated DNA used for GATA-3 DNA
affinity purification assay.
(B) Total cell extracts from EL4-Vector and
EL4-PU.1 (200, 400, or 800 g) were incu-
bated with biotinylated oligonucleotides and
levels of DNA bound GATA-3 were assessed
by Western (top). Total cell extracts were im-
munoblotted for GATA-3, followed by re-
probing for PU.1. Ratio of DNA bound
GATA-3 to total GATA-3 is indicated below.
(C) Total cell extracts (50 or 100 g) from IL-
4-low and IL-4-high Th2 cells were tested for
GATA-3 DNA binding levels (top) and total
levels of GATA-3 expression. Ratio of DNA
bound GATA-3 to total GATA-3 is indicated
below.
(D) Th2 cells were separated in IL-4-high and
IL-4-low populations, stimulated for 3 hr, and
fixed. Cells were lysed, chromatin sheared,
and fragments subjected to chromatin im-
munoprecipitation with or without anti-
GATA-3. DNA was purified from control and
GATA-3 ChIP and used as the template in a
PCR reaction for IL-4 promoter and 3# en-
hancer (Hypersensitivity Site VA). As a control, 4-fold dilutions of 1% of the ChIP input were used in PCR reactions with the same primer sets.
(E) Model of the IL-4 locus in IL-4-high and -low cells indicates that GATA-3 binds the IL-4 gene enhancer in IL-4 high cells but that PU.1
interferes with GATA-3 binding in IL-4-low cells. Cytokine profiles of IL-4-high and IL-4-low cells are also indicated.cytokine genes in the differentiated state (Agarwal and t
bRao, 1998; Bird et al., 1998; Avni et al., 2002). However,
these models do not account for the documented t
theterogeneity in Th2 populations. We propose that it is
the expression of specific transcription factors in sub-
ssets of Th2 cells that mediate this phenotype, and we
provide evidence in this report that PU.1 is such a d
pfactor. It is not clear whether PU.1 performs this func-
tion only in early cultures or plays a role in establishing l
4a distinct cellular phenotype as a stable phenomenon
in long-term cultures. IL-4-high and IL-4-low pheno- f
ctypes were described as heritable traits in Th2 clones
that are linked to the level of remodeling of the IL-4 i
plocus (Guo et al., 2002). Knowing that GATA-3 appears
to be responsible for aspects of chromatin remodeling n
sin Th2 cells (Lee et al., 2000), it is intriguing to speculate
that PU.1 may play a role in establishing these pro- t
tgrams in subsets of Th2 cells.
Our data show that interference of GATA-3 DNA bind- h
ming is one mechanism through which PU.1 regulates the
Th2 phenotype, though it is not mutually exclusive to p
Tother mechanisms. PU.1 may interact with distinct pro-
teins or regulate other genes required for this pheno- a
itype. Indeed, the ability of PU.1 mutants to differentially
affect Th2 cytokines (Figure 2) suggests that PU.1 may h
tregulate these genes through several mechanisms.
PU.1 may mediate indirect control of this phenotype K
cby altering expression or function of other transcription
factors, or work in concert with other factors to ulti- r
fmately decrease Th2 cytokine levels. PU.1 may also
mediate direct control of certain aspects of the IL-4- t
elow phenotype. In support of this, the DNA binding mu-
tant of PU.1 also has decreased ability to regulate Th2 a
lcytokine production (Figure 2G). Furthermore, PU.1 ex-
pression increases CCL22 production (Figure 4). How- e
ever, it is not clear that PU.1 DNA binding and interac-ion with GATA-3 can be separated since the PU.1 DNA
inding mutant also has decreased GATA-3 binding ac-
ivity (Figure 6). Additional studies must be performed
o distinguish these two functions of PU.1 in Th2 cells.
The regulation of PU.1 expression in T helper cells is
till under investigation. PU.1 expression diminishes in
eveloping Th1 cells and this occurs in a Stat4-inde-
endent manner. Moreover, Stat6 is required for estab-
ishing PU.1 expression in Th2 cultures (Figures 1 and
). Based on preliminary assays of intracellular staining
or PU.1, and the effects of PU.1 RNAi on increased
ytokine populations (Figure 5), we estimate that PU.1
s expressed in 10-20% of the total Th2 population. It is
ossible that stochastic expression of PU.1 and other
egative regulatory factors, in parallel with the in-
tructive expression of GATA-3, might explain the spec-
rum of initial Th2 cytokine expression profiles. Alterna-
ively, varying strengths of activation signal within the
eterogeneous activated population might provide a
ore directed program of Th2 cytokine expression. Im-
ortantly, PU.1 is expressed at w10-fold lower levels in
h2 cells compared to levels in myeloid cells. This
grees with the previously proposed concepts suggest-
ng that a continuum of PU.1 expression exists with
igh levels conferring a macrophage phenotype and in-
ermediate levels resulting in B cell development (De-
oter and Singh, 2000). This report adds to that con-
ept by demonstrating that a low level of PU.1 is
equired for regulating the Th2 phenotype. Thus, dif-
erent levels of PU.1 may be required for distinct func-
ions in specific cell types. Given that regulation of PU.1
xpression in myeloid cells is only partly understood
nd that it requires a large region surrounding the PU.1
ocus (Li et al., 2001), it is likely that control of PU.1
xpression in Th2 cells will be a complex issue.
The overall role of the IL-4-low Th2 cells in the im-
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701mune system is still unclear. These cells may develop
as a mechanism of limiting Th2 responses and immedi-
ate hypersensitivity in vivo arising from the probabilistic
restricted access of activating factors to the IL-4 locus
(Guo et al., 2002; Guo et al., 2004). In our model, PU.1
would prevent GATA-3 from completely remodeling Th2
cytokine loci, despite equal expression of GATA-3 in IL-4-
high and -low populations (Figure 7 and (Guo et al.,
2004)). However, the restricted ability of PU.1 to func-
tion as a negative regulator of certain genes in the Th2
phenotype may confer a specific in vivo function to
PU.1-expressing cells that might be required for some
Th2 mediated pathologies. IL-4-low cells express IL-21,
CCR4 and CCL22 at levels equal to or higher than IL-4-
high cells. It is possible that a Th2 subset expressing
IL-21, CCL22 and moderate levels of IL-10 and IL-13
may have a unique function in the Th2 response. For
example, Th2 cells expressing IL-13 and CCL22, even
in the absence of IL-4 production, would be potent in-
ducers of allergic inflammation. Future studies will ex-
amine the role of PU.1 in aspects of Th2-mediated in-
flammation.
In summary, we have identified PU.1 as a regulator
of the Th2 phenotype. PU.1 negatively regulates some,
but not all, parameters of the Th2 phenotype and is
expressed in subpopulations of Th2 cultures. PU.1
functions, at least in part, by directly binding to GATA-3
and interfering with GATA-3 DNA binding. These experi-
ments provide the basis for defining the role of PU.1 in
long-term Th2 cell phenotypes, in vivo Th2-mediated
immune pathology and furthering our understanding of
Th2 biology.
Experimental Procedures
Mice
Balb/c female mice (Harlan Bioscience, Indianapolis, IN) were used
for Th1 and Th2 cells differentiation. Stat4−/−, Stat6−/−, and
CD2:Stat6VT mice have been previously described (Kaplan et al.,
1996a; Kaplan et al., 1996b; Bruns et al., 2003). PU.1+/− mice on
the C57BL/6 background were kindly provided by Dr. Harinder
Singh, University of Chicago (Scott et al., 1994) and were back-
crossed five generations to the Balb/c genetic background for
transductions.
Th1 and Th2 Cell Differentiation
CD4+ T cells (greater than 97% pure by FACS analysis) from spleen
and lymph nodes were purified by positive selection using mag-
netic beads (Miltenyi Biotech, Auburn, CA). CD4+ T cells (106/ml) in
supplemented RPMI-1640 medium were activated with 2 g/ml
plate-bound anti-CD3 (145-2C11) + 0.5 g/ml soluble anti-CD28 in
the presence of 2 ng/ml IL-12 and 10 g/ml anti-IL-4 (11B11) for
Th1 differentiation or 10 ng/ml IL-4 + 10 g/ml anti-IFN-γ (R4/6A2)
for Th2 differentiation. After 3 days of culture, cells were expanded
and after a total of 6 days of incubation, differentiated Th1 or Th2
cell were centrifuged over Histopaque 1083 before restimulation
with anti-CD3. For long term Th2 differentiation, cells were resus-
pended at a concentration of 106/2 ml in the presence of cytokines
and antibodies for secondary Th2 differentiation. Cytokine levels in
the collected supernatants were analyzed by ELISA (Zhang et al.,
2000b). Statistics were performed using a t-test with SPSS software.
Northern Blot Analysis
Total RNA (10 g), extracted from differentiated Th1 and Th2 cells
using Trizol (Invitrogen Life Technologies, Carlsbad, CA) was frac-
tionated by electrophoresis through a 1% formaldehyde agarose
gel, transferred to a nylon membrane and hybridized with a 32P-
labeled cDNA probe specific to indicated genes. The PU.1 cDNAprobe DNA was a 400 bp SacI fragment (Klemsz and Maki, 1996).
Probes for IL-4, IL-5, IL-10, IL-13, CCL22, CCR4, and IL-21 were
generated by PCR and cloned into the pCR4 TOPO TA cloning vec-
tor (Invitrogen Life Technologies).
Immunoprecipitation and Western Blot Analysis
Nuclear and cytoplasmic proteins were prepared from differenti-
ated Th1 and Th2 cells using Nuclear and Cytoplasmic Extraction
Reagents (Pierce Biotechnology, Rockford, IL). Total cell extracts
from EL4-PU.1 cells, Th2 cells or Phoenix cells transfected with
control, PU.1-expressing or mutant PU.1, expressing retroviral vec-
tors were prepared as described (Chang et al., 2003). Total cell
lysates (8–10 mg EL4-PU.1 or Th2 extract) or Phoenix cell extracts
(1mg) were incubated with control antibody or anti-PU.1 and pro-
tein A-agarose, or anti-GATA3 conjugated with protein G beads (all
from Santa Cruz Biotechnology, Santa Cruz, CA), respectively, at
4oC overnight. The protein-antibody complexes were precipitated
by centrifugation at 10,000g for 1 min at 4°C and washed three
times in protein lysis buffer. Proteins were separated on a 12%
SDS-PAGE, and transferred onto Nytran membranes (Schleicher &
Schuell BioScience, Keene, NH). The blots were blocked in 3% dry
nonfat milk in PBS for 2 hr at room temperature, and probed with
anti-PU.1 or anti-GATA-3, and appropriate secondary reagents
(Bio-Rad, Hercules, CA) for 1 hr at room temperature. The final re-
action was developed with a Western Lightning Chemilumines-
cence Reagent Plus (PerkinElmer, Wellesley, MA). The blots were
stripped and reprobed with anti-PARP (Santa Cruz Biotechnology)
or anti-GAPDH (Biodesign International, Saco, ME) as controls.
DNA Oligo Pull-Down Experiment
Cytoplasmic, nuclear, or total protein extracts were incubated with
double-stranded biotinylated oligonucleotide as described (Chang
et al., 2003). The sequences for PU.1 binding oligonucleotides are
biotin-TGAATTAAGGAAGTAAGAAG and the reverse complement.
The sequences for GATA-3 binding oligonucleotides are biotin-
GGTGTCCTCTATCTGATTGTTAGCA and the reverse complement.
Precipitates were subjected to SDS-PAGE for Western blotting
analysis with anti-PU.1 antibodies or anti-GATA3 antibodies (Santa
Cruz Biotechnology).
Retroviral Vectors and Transduction
The coding region of a murine myc-tagged PU.1 cDNA or PU.1
mutants (Klemsz and Maki, 1996) were cloned into the MIEG-EGFP
vector (provided by W. Tao, Indiana University). A second retroviral
vector MIEG-hCD4 was made by replacing the EGFP with the hCD4
cDNA amplified from a cloned cDNA (provided by G. Alkhatib, Indi-
ana University). The coding region for murine GATA-3 cDNA was
amplified by PCR and cloned into MIEG-hCD4. The Phoenix-Eco
packaging cell line were transiently transfected with 24 g of each
purified plasmid by calcium phosphate precipitation. One day after
transfection, DMEM medium was replaced with RPMI-1640 com-
plete medium and cells were cultured at 32°C. After 1 and 2 days,
the supernatants containing retrovirus were collected, filtered
through 0.45 m filter and stored at –80°C. After 2 days of differen-
tiation, Th2 cells were transduced with 8 ml of the retroviral super-
natant containing 8 g/ml of polybrene, human IL-2 at 50 U/ml, and
cytokines and antibodies for Th2 differentiation by centrifugation
at 2000 rpm at 20°C for 30 min. For double transduction with both
PU.1 and GATA-3 retroviruses, 4 ml of each virus were mixed to-
gether for the spin infection. After the centrifugation, the retroviral
supernatant was replaced with RPMI-1640 medium containing
IL-4, human IL-2, anti-IFNγ, and anti-CD28. For infections during
the second week of culture, cells were transduced the day follow-
ing secondary activation and cultured for 4 to 5 days before analy-
sis. Transduction of PU.1 produced modest decreases in Th cell
viability. Transduction of PU.1 mutant cDNAs did not affect cell via-
bility. EL4 cells were transduced with control or PU.1-expressing
retroviruses (nontransduced EL4 cells lack detectable mRNA and
protein expression of PU.1), purified by sorting for EGFP expres-
sion and cultured for several weeks before use. PU.1-expressing
EL4 cells had decreased IL-4 production following PMA + iono-
mycin treatment compared to GFP-only expressing cells (data not
shown).
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SThe expression of IL-12Rβ2 and IL18Rα (BD Pharmingen [San Diego,
CA], R&D Systems [Minneapolis, MN]; PE-conjugated anti-hamster D
IIgG and APC-conjugated Streptavidin, [BD Pharmingen]) were
evaluated by flow cytometry using a FACScalibur instrument (Bec- L
ton Dickinson, Franklin Lakes, NJ). Results were analyzed by
CellQuest (Becton Dickinson) or WinMDI. Intracellular cytokine
Rstaining was performed by standard protocols using fluorochrome
Rconjugated antibodies (BD Pharmingen) to stain cells that had been
Aincubated in Monensin for the last two hours of a five hour anti-
PCD3 stimulation. In transduced cells, 5000 GFP+ events were col-
lected for each sample.
R
Isolation of IL-4-High and -Low Populations
ACD4+ T cells were differentiated into Th2 cells for 6 days as de-
oscribed above. The differentiated Th2 cells were stimulated with
1 g/ml plate bound anti-CD3 for 16 hr. Cells were harvested and A
washed with complete RPMI medium. The IL-4 secreting and non- r
secreting populations were separated using the Mouse IL-4 Secre- m
tion Assay (Miltenyi Biotec). Cells were expanded with human IL-2 (50
A
U/ml) for 3-4 days before restimulation. Supernatants were col-
e
lected after 1, 2, and 3 days stimulation.
t
c
RNA Interference: RNAi
ATwo PU.1 RNAi target sequences (PU.1 RNAi 1: AATGCATGACTAC
aTACTCCTT; PU.1 RNAi 2: ACTTCCCTGAGAACCACTT) were de-
tsigned based on tools from the OligoEngine (Seattle, WA) or as
ppreviously described (Zou et al., 2003). Complementary oligonucle-
Aotides were synthesized by Integrated DNA Technologies (Coral-
Aville, IA) and cloned into the RNAi-Ready pSIREN-RetroQ-ZsGreen
cvector (BD Biosciences Clontech, Palo Alto, CA). The PU.1 RNAi
6and a negative control supplied by the manufacturer were trans-
fected into Phoenix packaging cells to produce retroviral superna- B
tants as described above. RNAi transductions did not affect cell vi- M
ability. H
9
Semiquantitative Real-Time RT-PCR B
Total RNA from flow cytometry sorted naïve CD4+ cells, magnetic a
sorted naive CD4+ cells isolated each day during 5 days of differen- w
tiation (Miltenyi Biotec) or IL-4-high and -low cells following mag-
Bnetic sorting of CD2:Stat6VT CD4+ cells was reverse transcribed
owith the High-Capacity cDNA Archive Kit (Applied Biosystems,
sFoster City CA). PCR was performed on an Applied Biosystems ABI
oPRISM 7000 sequence detection system using Taqman Universal
CPCR Master Mix with commercially available primers and FAM la-
Kbeled probes (Assays on DemandTM, Applied Biosystems). Relative
cquantitation was performed using the comparative CT (threshold
cycle) method. Assays were performed in duplicate or triplicate and C
target gene  CT values were derived by subtraction of the CT value S
for β-2-microglobulin.  CT values were calculated relative to the f
chosen calibrator sample and relative gene expression levels were c
determined from the equation 2 - CT. Error bars represent the
D
range in relative gene expression level based on the  CT stan- S
dard deviation.
d
DChromatin Immunoprecipitation Assays (ChIP)
aChIP analysis was performed essentially as described (O’Sullivan
eet al., 2004) with the exception that nuclei were isolated by centrifu-
Dgation at 5000 rpm for 5 min and resuspended in nuclear lysis
pbuffer (50 mM Tris pH 8.0, 10 mM EDTA pH 7.5, 1% SDS, and prote-
mase inhibitor) at 4oC for 10 minutes and the addition of one wash
with a LiCl wash buffer (0.25 M LiCl, 1% Igepal, 1% sodium deoxy- F
cholate, 1 mM EDTA pH 8.0, and 10 mM Tris pH 8.0), and 2X with A
TE buffer (1 mM EDTA and 10 mM Tris pH 8.0). PCR was done with n
5 l (5 × 106 cells) of the immunoprecipitated DNA for 30 cycles as G
described (Avni et al., 2002).
F
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